These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35916346)

  • 1. Biological evaluation and in silico study of benzohydrazide derivatives as paraoxonase 1 inhibitors.
    Korkmaz IN; Türkeş C; Demir Y; Öztekin A; Özdemir H; Beydemir Ş
    J Biochem Mol Toxicol; 2022 Nov; 36(11):e23180. PubMed ID: 35916346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyl benzoate derivatives: in vitro Paraoxonase 1 inhibition and in silico studies.
    Korkmaz IN; Türkeş C; Demir Y; Özdemir H; Beydemir Ş
    J Biochem Mol Toxicol; 2022 Oct; 36(10):e23152. PubMed ID: 35708184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro inhibition effect of some coumarin compounds on purified human serum paraoxonase 1 (PON1).
    Gokce B; Gencer N; Arslan O; Karatas MO; Alici B
    J Enzyme Inhib Med Chem; 2016 Aug; 31(4):534-7. PubMed ID: 25982292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of thirty-eight cardiac drugs on human serum paraoxonase.
    Argan O; Cikrikci K; Uslu H; Gencer N
    Chem Biol Drug Des; 2022 Jul; 100(1):80-89. PubMed ID: 35395139
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Sever B; Kucukoglu K; Nadaroglu H; Altıntop MD
    Curr Comput Aided Drug Des; 2019; 15(2):136-144. PubMed ID: 29773067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the inhibitory effects and molecular docking of some sulfonamides on human serum paraoxonase 1.
    Alim Z; Kilic D; Koksal Z; Beydemir S; Ozdemir H
    J Biochem Mol Toxicol; 2017 Oct; 31(10):. PubMed ID: 28665493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition effect of some dihydroxy coumarin compounds on purified human serum paraoxonase 1 (PON1).
    Erzengin M; Basaran I; Cakir U; Aybey A; Sinan S
    Appl Biochem Biotechnol; 2012 Nov; 168(6):1540-8. PubMed ID: 22971832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some coumarins and benzoxazinones as potent paraoxonase 1 inhibitors.
    Karataş MO; Uslu H; Alıcı B; Gökçe B; Gencer N; Arslan O
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1386-91. PubMed ID: 26887799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some calcium-channel blockers: kinetic and
    Türkeş C; Demir Y; Beydemir Ş
    J Biomol Struct Dyn; 2022 Jan; 40(1):77-85. PubMed ID: 32783605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies.
    Tripathy RK; Aggarwal G; Bajaj P; Kathuria D; Bharatam PV; Pande AH
    Appl Biochem Biotechnol; 2017 Aug; 182(4):1642-1662. PubMed ID: 28161867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.
    Billecke S; Draganov D; Counsell R; Stetson P; Watson C; Hsu C; La Du BN
    Drug Metab Dispos; 2000 Nov; 28(11):1335-42. PubMed ID: 11038162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzenesulfonamide derivatives containing imine and amine groups: Inhibition on human paraoxonase and molecular docking studies.
    Işık M; Beydemir Ş; Demir Y; Durgun M; Türkeş C; Nasır A; Necip A; Akkuş M
    Int J Biol Macromol; 2020 Mar; 146():1111-1123. PubMed ID: 31739032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based contrast agents:
    Beydemir Ş; Türkeş C; Yalçın A
    Drug Chem Toxicol; 2021 Sep; 44(5):508-517. PubMed ID: 31179770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some indazoles reduced the activity of human serum paraoxonase 1, an antioxidant enzyme:
    Alım Z; Kılıç D; Demir Y
    Arch Physiol Biochem; 2019 Dec; 125(5):387-395. PubMed ID: 29741961
    [No Abstract]   [Full Text] [Related]  

  • 15. Naphthoquinones, benzoquinones, and anthraquinones: Molecular docking, ADME and inhibition studies on human serum paraoxonase-1 associated with cardiovascular diseases.
    Demir Y
    Drug Dev Res; 2020 Aug; 81(5):628-636. PubMed ID: 32232985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Human Serum Paraoxonase-I with Antimycotic Drugs: In Vitro and In Silico Studies.
    Türkeş C; Beydemir Ş
    Appl Biochem Biotechnol; 2020 Jan; 190(1):252-269. PubMed ID: 31342307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionalized imidazolium and benzimidazolium salts as paraoxonase 1 inhibitors: Synthesis, characterization and molecular docking studies.
    Karataş MO; Uslu H; Alıcı B; Gökçe B; Gencer N; Arslan O; Arslan NB; Özdemir N
    Bioorg Med Chem; 2016 Mar; 24(6):1392-401. PubMed ID: 26879855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking Studies and Inhibition Properties of Some Antineoplastic Agents against Paraoxonase-I.
    Demir Y; Türkeş C; Beydemir Ş
    Anticancer Agents Med Chem; 2020; 20(7):887-896. PubMed ID: 32067621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of in vitro effect, molecular docking, and molecular dynamics simulations of some dihydropyridine-class calcium channel blockers on human serum paraoxonase 1 (hPON1) enzyme activity.
    Gökçe B; Muhammed MT
    Biotechnol Appl Biochem; 2023 Oct; 70(5):1707-1719. PubMed ID: 37071114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic drugs: in vitro paraoxonase 1 inhibition and molecular docking studies.
    Çalışkan B; Demir Y; Türkeş C
    Biotechnol Appl Biochem; 2022 Dec; 69(6):2273-2283. PubMed ID: 34786760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.